We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 02, 2021

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs T-DM1 in ERBB2-Positive Breast Cancer

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
JAMA Oncol 2021 Jun 24;[EPub Ahead of Print], T Hatschek, T Foukakis, J Bjöhle, T Lekberg, H Fredholm, E Elinder, A Bosch, G Pekar, H Lindman, A Schiza, Z Einbeigi, J Adra, A Andersson, L Carlsson, AC Dreifaldt, E Isaksson-Friman, S Agartz, E Azavedo, P Grybäck, M Hellström, H Johansson, C Maes, I Zerdes, J Hartman, Y Brandberg, J Bergh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading